What were the key takeaways from Summit Therapeutics’s earnings call?

What is the revenue and EPS growth rate for Summit Therapeutics year over year?

What is Summit Therapeutics's gross profit margin?

What is Summit Therapeutics's latest dividend and current dividend yield?

What guidance did Summit Therapeutics's management provide for the next earnings period?

What were the key takeaways from Summit Therapeutics's earnings call?

Did Summit Therapeutics beat or miss consensus estimates last quarter?

What factors drove the changes in Summit Therapeutics's revenue and profit?

- **Breakthrough NSCLC Data**: ivonescimab + chemo delivered 4.24-month PFS improvement (HR 0.60) in HARMONi-6, outperforming tislelizumab across PD-L1 subgroups.
- **Global Expansion**: 14 Phase III studies underway, including first colorectal cancer trial with 600-patient enrollment.
- **FDA Filing Momentum**: BLA submission for EGFR-mutant NSCLC planned Q4 2025; $238.6M cash runway supports aggressive development.
- **Safety Validation**: ivonescimab tolerable in high-risk squamous NSCLC patients with central tumors and hemoptysis history.

**【Management Opening Remarks】**
- Announced Phase III expansion into colorectal cancer and global Phase III study for ivonescimab.
- Highlighted HARMONi-6 data showing 4.24-month PFS improvement vs. tislelizumab in squamous NSCLC.
- BLA submission for ivonescimab + chemo in EGFR-mutant NSCLC planned Q4 2025.

**【CEO Commentary】**
- **HARMONi-6 Results**: 11.14m vs. 6.90m PFS (HR 0.60, p<0.0001), benefit across PD-L1 subgroups, tolerable safety profile.
- Expanded Phase III program to 14 studies across 6 tumor types, including colorectal cancer.
- Protocol amendment for HARMONi-3 to separate squamous and non-squamous analyses, increasing sample size to 1,600 patients.

**【CFO Financial Update】**
- Q3 2025 cash position: $238.6M.
- GAAP operating expenses: $234.2M (down 56% vs. Q2 2025 due to $348M stock comp reversal).
- Non-GAAP operating expenses: $103.4M (up 15% vs. Q2 2025 due to R&D spend on HARMONi-3/7).

**【Q&A Highlights】**
- **FDA Interactions**: BLA submission includes mature data; FDA requires OS benefit for approval, but totality of data (PFS, ORR, safety) supports filing.
- **Funding Strategy**: $350M ATM available; no immediate plans for equity raise, but open to strategic options.
- **Colorectal Trial**: Phase III HARMONi-GI3 to enroll 600 patients, U.S. sites activating Q4 2025.
- **OS Data Timing**: HARMONi-6 OS analysis expected 2026; HARMONi-3 squamous cohort PFS readout Q2 2026.


Summit Therapeutics Inc. (SMMT) Q3 2025 Earnings Call Transcript

- **China Regulatory Breakthrough**: First global Phase III data validation with NMPA approval for frontline NSCLC.
- **PFS/OS Duality**: HARMONi-6 PFS win & 0.777 OS HR vs. pembro highlight ivonescimab's potential as PD-1 replacement.
- **Global Expansion Momentum**: 11 Phase III trials, 30+ ISTs, & $361M cash to fuel 2025 HARMONi readout & commercial launch.

**【CEO & Co-Founder Overview】**
- **China Regulatory Milestone**: Ivonescimab approved as frontline monotherapy for PD-L1+ NSCLC in China, marking first global Phase III data validation.
- **Pivotal Trial Success**: HARMONi-6 Phase III trial met PFS endpoint vs. tislelizumab + chemo, showing statistically significant benefit in squamous NSCLC.
- **Global Expansion**: 11 Phase III trials underway across NSCLC, HNSCC, BTC, TNBC, with 30+ ISTs approved to date.

**【CFO Financial Update】**
- **Cash Position**: $361M as of Q1 2025, debt-free with >24 months of runway.
- **Operational Scale**: Q1 2025 non-GAAP R&D/G&A expenses: $47.1M / $8.6M, stable vs. prior quarter.
- **Commercial Prep**: Hired Chief Commercial Officer & 30+ commercial team members ahead of mid-2025 HARMONi readout.

**【Q&A Highlights】**
- **HARMONi Data Expectations**: Dual PFS/OS primary endpoints; 39% OS maturity shows 0.777 HR vs. pembro, aligning with Akeso's China experience.
- **Competitive Positioning**: Ivonescimab's VEGF/PD-1 dual targeting differentiated from single-agent PD-1s; HARMONi-3 expansion to non-squamous histology doubles addressable market.
- **Manufacturing Security**: Dual supply chain with Akeso & CMOs; API IP protected until 2040s.

Summit Therapeutics (SMMT)-1 May 25-2025 Q1 Earnings call transcript

- **Strategic collaboration**: Pfizer partnership to evaluate Ivonescimab + ADCs in solid tumors, trials starting mid-2025.
- **Expanded NSCLC trials**: HARMONi-3 now includes non-squamous patients, tripling addressable population; HARMONi-7 initiated for PD-L1 high NSCLC.
- **Financial strength**: $412M cash, no debt; R&D expenses up 150% YoY to support clinical expansion.
- **Broad oncology potential**: Ivonescimab Phase II data shows promise in 7 tumor types, targeting $90B checkpoint inhibitor market.

**【CEO & Co-CEO Opening Remarks】**
- **Ivonescimab clinical momentum**: Announced collaboration with Pfizer to evaluate Ivonescimab in combination with ADCs in solid tumors, with trials expected to start mid-2025.
- **Phase III trial updates**: HARMONi (EGFR-mutated NSCLC) top-line data expected mid-2025; HARMONi-3 expanded to include non-squamous NSCLC, addressing 2-3x larger patient population.
- **Global expansion**: Initiated HARMONi-7 trial for first-line PD-L1 high NSCLC, with sites activating in the U.S.

**【CFO Financial Update】**
- **Cash position**: $412M as of Q4 2024, debt-free, supporting clinical expansion.
- **R&D expenses**: $150.8M (GAAP) / $134.8M (non-GAAP) FY2024, driven by Ivonescimab trials.
- **Cost efficiency**: Non-GAAP operating expenses down 70% YoY to $175.3M, excluding one-time Akeso licensing costs.

**【Q&A Key Highlights】**
- **Pfizer collaboration details**: Phase 1b/2 trials combining Ivonescimab with vedotin-based ADCs; Pfizer covers costs, Summit provides drug supply.
- **HARMONi trial timelines**: HARMONi-3 non-squamous enrollment underway in U.S., global sites to activate Q2 2025; HARMONi-6 (Akeso-led squamous NSCLC) expected readout mid-2025.
- **Market potential**: Ivonescimab targeting $20B NSCLC market and $90B checkpoint inhibitor landscape; Phase II data shows promise in colorectal, ovarian, and gastric cancers.
- **Competitive positioning**: Ivonescimab's dual PD-1/VEGF mechanism may offer superior efficacy vs. monotherapy checkpoint inhibitors.


SMMT

SMMT fundamentals

Earnings Call

You can ask Aime